{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:35:08Z","timestamp":1715945708671},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10165-010-0292-8","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T09:55:23Z","timestamp":1270720523000},"page":"381-388","source":"Crossref","is-referenced-by-count":1,"title":["Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model"],"prefix":"10.1093","volume":"20","author":[{"given":"Chikako","family":"Setoguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Katsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Aono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,4,9]]},"reference":[{"key":"292_CR1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EHS Choy","year":"2001","unstructured":"Choy EHS, Panayi GS. Mechanisms of disease: cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907\u201316.","journal-title":"N Engl J Med"},{"key":"292_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2169\/internalmedicine.42.15","volume":"42","author":"PC Taylor","year":"2003","unstructured":"Taylor PC. Anti-TNF-\u03b1 therapy for rheumatoid arthritis: an update. Intern Med. 2003;42:15\u201320.","journal-title":"Intern Med"},{"key":"292_CR3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167\u201379.","journal-title":"N Engl J Med"},{"key":"292_CR4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Du Pan","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler H, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560\u20138.","journal-title":"Arthritis Rheum"},{"key":"292_CR5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor \u03b1 agent to a second anti-tumor necrosis factor \u03b1 agent in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:13\u201320.","journal-title":"Arthritis Rheum"},{"key":"292_CR6","first-page":"260","volume":"24","author":"M Nagashima","year":"2006","unstructured":"Nagashima M, Matsuoka T, Saitoh K, Koyama T, Kikuchi O, Toshino S. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, bucillamine in 1358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:260\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"292_CR7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/s10165-005-0420-z","volume":"15","author":"Y Ichikawa","year":"2005","unstructured":"Ichikawa Y, Saito S, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323\u20138.","journal-title":"Mod Rheumatol"},{"key":"292_CR8","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","volume":"43","author":"AM Bendele","year":"2000","unstructured":"Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000;43:2648\u201359.","journal-title":"Arthritis Rheum"},{"key":"292_CR9","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2518","volume":"10","author":"M Daans","year":"2008","unstructured":"Daans M, Lories RJU, Luyten FP. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Res Ther. 2008;10:R115.","journal-title":"Arthritis Res Ther"},{"key":"292_CR10","first-page":"691","volume":"18","author":"M Hayashi","year":"1991","unstructured":"Hayashi M, Matsunaga K, Okahara A, Mita S. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats. J Rheumatol. 1991;18:691\u20135.","journal-title":"J Rheumatol"},{"key":"292_CR11","first-page":"953","volume":"20","author":"K Hashimoto","year":"1993","unstructured":"Hashimoto K, Lipsky PE. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol. 1993;20:953\u20137.","journal-title":"J Rheumatol"},{"key":"292_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/clin.1993.1006","volume":"66","author":"S Hirohata","year":"1993","unstructured":"Hirohata S, Lipsky PE. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol. 1993;66:43\u201351.","journal-title":"Clin Immunol Immunopathol"},{"key":"292_CR13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/art.1780370625","volume":"37","author":"S Hirohata","year":"1994","unstructured":"Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and d-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994;37:942\u201350.","journal-title":"Arthritis Rheum"},{"key":"292_CR14","first-page":"65","volume":"22","author":"H Aono","year":"1995","unstructured":"Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol. 1995;22:65\u201370.","journal-title":"J Rheumatol"},{"key":"292_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0192-0561(98)00012-5","volume":"20","author":"H Matsuno","year":"1998","unstructured":"Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs\u2014the disulfide structure of SA96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol. 1998;20:295\u2013304.","journal-title":"Int J Immunopharmacol"},{"key":"292_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2249.1999.00876.x","volume":"116","author":"M Nagashima","year":"1999","unstructured":"Nagashima M, Yoshino S, Aono H, Takai M, Sasano M. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol. 1999;116:360\u20135.","journal-title":"Clin Exp Immunol"},{"key":"292_CR17","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1073\/pnas.132026099","volume":"99","author":"F Amersi","year":"2002","unstructured":"Amersi F, Nelson SK, Shen XD, Kato H, Melinek J, Kupiec-Weglinski JW, et al. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci USA. 2002;99:8915\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"292_CR18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.intimp.2007.07.020","volume":"7","author":"F Tsuji","year":"2007","unstructured":"Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL-1\u03b2-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol. 2007;7:1569\u201376.","journal-title":"Int Immunopharmacol"},{"key":"292_CR19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00011-009-0021-y","volume":"58","author":"K Oki","year":"2009","unstructured":"Oki K, Tsuji F, Ohashi K, Kageyama M, Aono H, Sasano M. The investigation of synovial genomic targets of bucillamine with microarray technique. Inflamm Res. 2009;58:571\u201384.","journal-title":"Inflamm Res"},{"key":"292_CR20","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","volume":"167","author":"CS Via","year":"2001","unstructured":"Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-\u03b1 promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167:6821\u20136.","journal-title":"J Immunol"},{"key":"292_CR21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2492\/inflammregen.27.516","volume":"27","author":"N Odani","year":"2007","unstructured":"Odani N, Mukai Y, Tsuji F, Aono H, Okamoto M, Sasano M. Combination effect of bucillamine and methotrexate on rat type II collagen-induced arthritis model. Inflamm Regen. 2007;27:516\u201321.","journal-title":"Inflamm Regen"},{"key":"292_CR22","first-page":"2095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095\u2013147.","journal-title":"Blood"},{"key":"292_CR23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.191.2.313","volume":"191","author":"R Horai","year":"2000","unstructured":"Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313\u201320.","journal-title":"J Exp Med"},{"key":"292_CR24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar318","volume":"3","author":"AD Cook","year":"2001","unstructured":"Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3:293\u20138.","journal-title":"Arthritis Res"},{"key":"292_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/ard.2006.057182","volume":"66","author":"C Plater-Zyberk","year":"2007","unstructured":"Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis. 2007;66:452\u20137.","journal-title":"Ann Rheum Dis"},{"key":"292_CR26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1084\/jem.194.7.873","volume":"194","author":"JL McQualter","year":"2001","unstructured":"McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194:873\u201382.","journal-title":"J Exp Med"},{"issue":"Suppl 3","key":"292_CR27","first-page":"124","volume":"68","author":"G Burmester","year":"2009","unstructured":"Burmester G, Wagner F, Feist E, Sleeman M, Grove G, White B. CAM-3001, a novel human monoclonal antibody against GM-CSF receptor-a, in subjects with rheumatoid arthritis (RA): results of a first-time in human study. Ann Rheum Dis. 2009;68[Suppl 3]:124.","journal-title":"Ann Rheum Dis"},{"key":"292_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/08830189809042997","volume":"16","author":"T Hirano","year":"1998","unstructured":"Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16:249\u201384.","journal-title":"Int Rev Immunol"},{"key":"292_CR29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q","volume":"42","author":"M Sasai","year":"1999","unstructured":"Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999;42:1635\u201343.","journal-title":"Arthritis Rheum"},{"key":"292_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2474-10-23","volume":"10","author":"F Tsuji","year":"2009","unstructured":"Tsuji F, Yoshimi M, Katsuta O, Takai M, Ishihara K, Aono H. Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA\/1J mice. BMC Musculoskelet Disord. 2009;10:23.","journal-title":"BMC Musculoskelet Disord"},{"key":"292_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","volume":"2","author":"N Nishimoto","year":"2006","unstructured":"Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619\u201326.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"292_CR32","first-page":"65","volume":"23","author":"H Aono","year":"1996","unstructured":"Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol. 1996;23:65\u201370.","journal-title":"J Rheumatol"},{"key":"292_CR33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"2","author":"FM Brenann","year":"1989","unstructured":"Brenann FM, Chantry D, Jakson A, Maini RN, Feldmann M. Inhibitory effects of TNF\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244\u20137.","journal-title":"Lancet"},{"key":"292_CR34","first-page":"225","volume":"6","author":"D Butler","year":"1995","unstructured":"Butler D, Maini RN, Feldmann M, Brenann FM. Blockade of TNF\u03b1 with chimeric anti-TNF\u03b1 monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA MNC cultures. A comparison with IL-1ra. Eur Cytokine Netw. 1995;6:225\u201330.","journal-title":"Eur Cytokine Netw"},{"key":"292_CR35","first-page":"876","volume":"83","author":"C Haworth","year":"1991","unstructured":"Haworth C, Brenann FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. 1991;83:876\u201382.","journal-title":"J Clin Invest"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-010-0292-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:06Z","timestamp":1646843106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-010-0292-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s10165-010-0292-8","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,9]]}}}